Neovascular age-related macular degeneration (nAMD ) and diabetic macular edema (DME) are retinal diseases that are the two leading causes of vision loss, affecting more than 40 million people worldwide. Roche recentlyRead More…
Distinctive BsAb Platform The problem of chain mismatches will reduce the yield of the bsAb, increase the difficulty of purification, and increase the production cost. Therefore, obtaining a correctly assembled bsAb hasRead More…
Bispecific antibody (bsAb) refers to a molecule that can bind to two different antigens or to two different epitopes of the same antigen. The concept of bsAbs was first proposed by NisonoffRead More…
In the past two decades, advances in biotechnology have brought improvements in protein engineering and manufacturing technology, and promoted the development of increasingly complex bispecific antibodies (BsAbs). At present, more than 100Read More…
Nowadays, in the tide of research and development of biological agents, antibody drugs are in an explosive period. The major monoclonal antibody (McAb) drugs have accounted for more than half of theRead More…
In 1960, Nisonoff and his collaborators at the Roswell Park Memorial Institute in New York first proposed the original concept of bispecific antibodies (BsAbs). Since then, with the great progress in theRead More…
TG Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for patients with B-cell-mediated diseases. Recently, the company announced the launch of TG-1801 ‘s first human Phase I study, a new,Read More…